Atripla is now the most prescribed treatment for patients starting HIV therapy in the U.S., according to the company, and it is expected to bring in more than $1 billion in sales this year.

Today, Baltimore and other cities are choosing intranasal naloxone for community use — naloxone that can be sprayed into the nostril and doesn’t require needles.